OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Substance Abuse Treatment is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study	67
The impact of military sexual trauma and gender on receipt of evidence-based medication treatment among veterans with opioid use disorder	64
Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail	62
Emergency department interventions for opioid use disorder: A synthesis of emerging models	60
A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts	60
Education and careers were our way out	52
Serial mediation analysis of treatment-specific processes in two contrasting alcohol treatments	40
C2: editorial board	33
What is the relapse risk during treatment? Survivor analysis of single and multiple relapse events in inpatients with alcohol use disorder as part of an observational study	33
Can nicotine replacement therapy be personalized? A statistical learning analysis	32
What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings	32
A randomized clinical trial evaluating the impact of counselor training and patient feedback on substance use disorder patients' sexual risk behavior	32
Adapting methadone inductions to the fentanyl era	31
Suboptimal nonmedical qualities of primary care linked with care avoidance among people who use drugs in a Canadian setting amid an integrated health care reform	30
A randomized clinical trial of strengths-based case management to link emergency department patients to opioid use disorder treatment	28
Mobile-based brief interventions targeting cannabis-impaired driving among youth: A Delphi study	26
Improving geographic access to methadone clinics	26
Using machine learning to examine predictors of treatment goal change among individuals seeking treatment for alcohol use disorder	25
The impact of social network dynamics on engagement in drug use reduction programs among men and women who use drugs	25
Drug court utilization of medications for opioid use disorder in high opioid mortality communities	24
Scoping review of interventions to link individuals to substance use services at discharge from jail	24
Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder	24
Associations between prescription and illicit stimulant and opioid use in the United States, 2015–2020	24
Knowledge, attitudes, and behaviors related to the fentanyl-adulterated drug supply among people who use drugs in Oregon	24
Recidivism prevention for impaired driving: Longitudinal 5-year outcomes from Quebec's severity-based intervention assignment program	24

Adapting and scaling a single site DEA X-waiver training program to a statewide initiative: Implementing GetWaiveredTX	24
Developing a cascade of care for opioid use disorder among individuals in jail	23
The impact of COVID-19 on health care professionals who are exposed to drug-related deaths while supporting clients experiencing addiction	23
Racial disparities in linkage to care among patients with substance use disorders	23
TOC (update)	23
C2: editorial board	22
Follow-up after ED visits for opioid use disorder: Do they reduce future overdoses?	22
C2: editorial board	22
Patient-centered primary care and receipt of evidence-based alcohol-related care in the national Veterans Health Administration	21
Alcohol and drug use among bartenders: An at risk population?	21
Consumer access to buprenorphine and methadone in certified community behavioral health centers: A secret shopper study	19
Client attitudes toward virtual treatment court	18
Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder	17
Prescribing buprenorphine for opioid use disorder in primary care: A survey of French general practitioners in the Sentinelles network	17
Opioid relapse and MOUD outcomes following civil commitment for opioid use	17
Experiences of stigma in hospitals with addiction consultation services: A qualitative analysis of patients' and hospital-based providers' perspectives	16
Accessibility of substance use treatment: A qualitative study from the non-service users' perspective	15
Behavioral activation for depression delivered by drug and alcohol treatment workers: A pilot randomized controlled trial	15
A systematic literature review of clinical trials and therapeutic applications of ibogaine	15
Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes	15
A cohort study examining the relationship among housing status, patient characteristics, and retention among individuals enrolled in low-barrier-to-treatment-access methadone maintenance treatment	15
“In their mind, they always felt less than”: The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention	14
TOC (update)	14
Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic	13
Traditions and Connections for Urban Native Americans (TACUNA): Utilizing community-based input to develop an opioid prevention intervention for urban American Indian/Alaska Native emerging adults	13
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder	13
Poking the bear: The inapplicability of the RNR principles for justice-involved women	13
From there to here: A journey through substance use disorder, prison, and recovery	13
The impact of race, gender, and heroin use on opioid addiction stigma	13
Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma	12
Emergency department utilization by individuals with opioid use disorder who were recently incarcerated	12
TOC (update)	12
Modeling the cost and impact of injectable opioid agonist therapy on overdose and overdose deaths	11
Cascade of care for office-based buprenorphine treatment in Bronx community clinics	11
Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review	11
Characterizing nicotine withdrawal in smokers experiencing homelessness	11
“If I had them, I would use them every time”: Perspectives on fentanyl test strip use from people who use drugs	10
National trends in buprenorphine prescribing before and during the COVID-19 pandemic	10
A randomized pilot trial of a mobile phone–based brief intervention with personalized feedback and interactive text messaging to reduce driving after cannabis use and riding with a cannabis impaired d	10
TOC (update)	10
HealthCall: A randomized trial assessing a smartphone enhancement of brief interventions to reduce heavy drinking in HIV care	10
Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing	10
Factors associated with clinician treatment recommendations for patients with a new diagnosis of opioid use disorder	10
TOC (update)	10
The phenotype of recovery VIII: Association among delay discounting, recovery capital, and length of abstinence among individuals in recovery from substance use disorders	9
Predictors of therapeutic alliance, treatment feedback, and clinical outcomes among African American women in treatment for co-occurring PTSD and SUD	9
Ethnic discrimination and alcohol-related problem severity among Hispanic/Latin drinkers: The role of social anxiety in the minority stress model	9
C2: editorial board	9
Homelessness and publicly funded substance use disorder treatment in California, 2016–2019: Analysis of treatment needs, level of care placement, and outcomes	9
Evaluating disparities in prescribing of naloxone after emergency department treatment of opioid overdose	9

Community coalition and key stakeholder perceptions of the community opioid epidemic before an intensive community-level intervention